Physician profile
Michael Ronald Mitchell
NPI 1669436655
$1,108.89
in general payments reported to CMS, 2019-2025
21 companies · $14.77 in 2025
The $14.77 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $696 · 2020: $208 · 2021: $35.60 · 2023: $155 · 2025: $14.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $169.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $154.96 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Sanofi-Aventis U.S. LLC | $149.98 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $139.89 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $133.41 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $90.51 | 2019 | |
| Amgen INC. | $66.29 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $55.76 | 2019 | |
| Bardy Diagnostics, INC. | $55.00 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $40.63 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $31.86 | 2019 | |
| Novo Nordisk INC | $28.94 | 2021 | |
| Boston Scientific Corporation | $22.59 | 2019 | |
| Astellas Pharma US INC | $18.03 | 2019 | |
| Braemar Manufacturing, LLC | $15.71 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Osprey Medical INC | $15.00 | 2019 | |
| Mannkind Corporation | $14.77 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $12.78 | 2019 | |
| Abbott Laboratories | $12.65 | 2019 | |
| Amarin Pharma, INC. | $11.47 | 2019 | |
| Clarus Therapeutics INC. | $6.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.